title: Risk Factors of Subacute Thrombosis After Intracranial Stenting for Symptomatic Intracranial Arterial Stenosis.
abstract: We aimed to explore the risk factors of subacute thrombosis (SAT) after intracranial stenting for patients with symptomatic intracranial arterial stenosis.
  
  
  
  From January to December 2013, all symptomatic intracranial arterial stenosis patients who underwent intracranial stenting in Beijing Tiantan Hospital were prospectively registered into this study. Baseline clinical features and operative data were compared in patients who developed SAT with those who did not. Binary logistic regression model was used to determine the risk factors associated with SAT.
  
  
  
  Of the 221 patients enrolled, 9 (4.1%) cases had SAT 2 to 8 days after stenting. Binary logistic analysis showed that SAT was related with tandem stenting (odds ratio [OR], 11.278; 95% confidence interval [CI], 2.422-52.519) and antiplatelet resistance (aspirin resistance: OR, 6.267; 95% CI, 1.574-24.952; clopidogrel resistance: OR, 15.526; 95% CI, 3.105-77.626; aspirin and clopidogrel resistance: OR, 12.246; 95% CI, 2.932-51.147; and aspirin or clopidogrel resistance: OR, 11.340; 95% CI, 2.282-56.344).
  
  
  
  Tandem stenting and antiplatelet resistance might contribute to the development of SAT after intracranial stenting in patients with symptomatic intracranial arterial stenosis.
authors.affiliation: From the Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (X.S., D.M., F.G., N.M., B.W., Z.M.); China National Clinical Research Center for Neurological Diseases Center of Stroke, Beijing (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Institute for Brain Disorders, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Department of Neurology, Tangshan Gongren Hospital, Hebei Medical University, China (X.T.); and Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China (W.T.L.).
authors.forename: Xuan
authors.initials: X
authors.lastname: Sun
authors.affiliation: From the Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (X.S., D.M., F.G., N.M., B.W., Z.M.); China National Clinical Research Center for Neurological Diseases Center of Stroke, Beijing (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Institute for Brain Disorders, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Department of Neurology, Tangshan Gongren Hospital, Hebei Medical University, China (X.T.); and Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China (W.T.L.).
authors.forename: Xu
authors.initials: X
authors.lastname: Tong
authors.affiliation: From the Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (X.S., D.M., F.G., N.M., B.W., Z.M.); China National Clinical Research Center for Neurological Diseases Center of Stroke, Beijing (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Institute for Brain Disorders, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Department of Neurology, Tangshan Gongren Hospital, Hebei Medical University, China (X.T.); and Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China (W.T.L.).
authors.forename: Wai Ting
authors.initials: WT
authors.lastname: Lo
authors.affiliation: From the Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (X.S., D.M., F.G., N.M., B.W., Z.M.); China National Clinical Research Center for Neurological Diseases Center of Stroke, Beijing (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Institute for Brain Disorders, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Department of Neurology, Tangshan Gongren Hospital, Hebei Medical University, China (X.T.); and Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China (W.T.L.).
authors.forename: Dapeng
authors.initials: D
authors.lastname: Mo
authors.affiliation: From the Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (X.S., D.M., F.G., N.M., B.W., Z.M.); China National Clinical Research Center for Neurological Diseases Center of Stroke, Beijing (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Institute for Brain Disorders, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Department of Neurology, Tangshan Gongren Hospital, Hebei Medical University, China (X.T.); and Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China (W.T.L.).
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.affiliation: From the Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (X.S., D.M., F.G., N.M., B.W., Z.M.); China National Clinical Research Center for Neurological Diseases Center of Stroke, Beijing (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Institute for Brain Disorders, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Department of Neurology, Tangshan Gongren Hospital, Hebei Medical University, China (X.T.); and Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China (W.T.L.).
authors.forename: Ning
authors.initials: N
authors.lastname: Ma
authors.affiliation: From the Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (X.S., D.M., F.G., N.M., B.W., Z.M.); China National Clinical Research Center for Neurological Diseases Center of Stroke, Beijing (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Institute for Brain Disorders, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Department of Neurology, Tangshan Gongren Hospital, Hebei Medical University, China (X.T.); and Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China (W.T.L.).
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
authors.affiliation: From the Department of Interventional Neurology, Beijing Tiantan Hospital, Capital Medical University, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, China (X.S., D.M., F.G., N.M., B.W., Z.M.); China National Clinical Research Center for Neurological Diseases Center of Stroke, Beijing (X.S., D.M., F.G., N.M., B.W., Z.M.); Beijing Institute for Brain Disorders, China (X.S., D.M., F.G., N.M., B.W., Z.M.); Department of Neurology, Tangshan Gongren Hospital, Hebei Medical University, China (X.T.); and Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China (W.T.L.). zhongrongm@163.com.
authors.forename: Zhongrong
authors.initials: Z
authors.lastname: Miao
mesh_terms: D000328:Adult; D000368:Aged; D001241:Aspirin / Q000627:therapeutic use; D000077144:Clopidogrel; D003251:Constriction, Pathologic / Q000628:therapy*; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects*; D013927:Thrombosis / Q000188:drug therapy*; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin
keywords: aspirin; odds ratio; perfusion imaging; risk factors; thrombosis